Free Trial

Hikma Pharmaceuticals (HIK) Stock Forecast & Price Target

Hikma Pharmaceuticals logo
GBX 1,950 +78.00 (+4.17%)
(As of 11/22/2024 ET)

Hikma Pharmaceuticals - Analysts' Recommendations and Stock Price Forecast (2024)

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Consensus Rating

Sell
0
Hold
1
Buy
2

Based on 3 Wall Street analysts who have issued ratings for Hikma Pharmaceuticals in the last 12 months, the stock has a consensus rating of "Moderate Buy." Out of the 3 analysts, 1 has given a hold rating, and 2 have given a buy rating for HIK.

Consensus Price Target

GBX 2,383.33
According to the 3 analysts' twelve-month price targets for Hikma Pharmaceuticals, the average price target is GBX 2,383.33. The highest price target for HIK is GBX 2,750, while the lowest price target for HIK is GBX 2,000. The average price target represents a forecasted upside of 22.22% from the current price of GBX 1,950.
Get the Latest News and Ratings for HIK and Related Stocks

Enter your email address to receive the latest news and analysts' ratings for Hikma Pharmaceuticals and its competitors.

Sign Up

HIK Analyst Ratings Over Time

TypeCurrent Forecast
11/24/23 to 11/23/24
1 Month Ago
10/25/23 to 10/24/24
3 Months Ago
8/26/23 to 8/25/24
1 Year Ago
11/24/22 to 11/24/23
Strong Buy
0 Strong Buy rating(s)
0 Strong Buy rating(s)
0 Strong Buy rating(s)
0 Strong Buy rating(s)
Buy
2 Buy rating(s)
2 Buy rating(s)
3 Buy rating(s)
3 Buy rating(s)
Hold
1 Hold rating(s)
2 Hold rating(s)
3 Hold rating(s)
3 Hold rating(s)
Sell
0 Sell rating(s)
0 Sell rating(s)
0 Sell rating(s)
0 Sell rating(s)
Consensus Price TargetGBX 2,383.33GBX 2,325GBX 2,250GBX 1,972.50
Consensus Rating
Moderate Buy
Moderate Buy
Moderate Buy
Moderate Buy

HIK Analyst Recommendations By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.
Skip Chart & View Analyst Rating History

HIK Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.
Skip Chart and View Analyst Price Target HistorySkip Chart & View Price History Table

Hikma Pharmaceuticals Stock vs. The Competition

TypeHikma PharmaceuticalsMedical Companies
Consensus Rating Score
2.67
2.80
Consensus RatingModerate BuyModerate Buy
News Sentiment Rating
Neutral News

See Recent HIK News
Neutral News
DateBrokerageAnalyst NameActionRatingPrice TargetUpside/Downside on Report DateDetails
9/2/2024Berenberg Bank
2 of 5 stars
 UpgradeBuyGBX 2,100 ➝ GBX 2,400+20.12%
6/18/2024Deutsche Bank Aktiengesellschaft
3 of 5 stars
 Reiterated RatingBuyGBX 2,750+38.05%
5/7/2024Barclays
3 of 5 stars
 Reiterated RatingEqual WeightGBX 2,000+1.47%
11/13/2023Royal Bank of Canada
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Reiterated RatingSector PerformGBX 2,150+22.16%
10/16/2023JPMorgan Chase & Co.
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Reiterated RatingOverweight
10/3/2023Citigroup
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Reiterated RatingBuy
5/22/2023Jefferies Financial Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetBuyGBX 2,080 ➝ GBX 2,125+15.46%

Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Saturday at 10:00 PM ET.


HIK Forecast - Frequently Asked Questions

According to the research reports of 3 Wall Street equities research analysts, the average twelve-month stock price forecast for Hikma Pharmaceuticals is GBX 2,383.33, with a high forecast of GBX 2,750 and a low forecast of GBX 2,000.

3 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Hikma Pharmaceuticals in the last twelve months. There is currently 1 hold rating and 2 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "moderate buy" HIK shares.

According to analysts, Hikma Pharmaceuticals's stock has a predicted upside of 22.22% based on their 12-month stock forecasts.

Over the previous 90 days, Hikma Pharmaceuticals's stock had 1 upgrade by analysts.

Hikma Pharmaceuticals has been rated by research analysts at Berenberg Bank in the past 90 days.

Analysts like Hikma Pharmaceuticals less than other "medical" companies. The consensus rating score for Hikma Pharmaceuticals is 2.67 while the average consensus rating score for "medical" companies is 2.80. Learn more on how HIK compares to other companies.


This page (LON:HIK) was last updated on 11/23/2024 by MarketBeat.com Staff
From Our Partners